Clinical Trials Logo

Metabolic Syndrome X clinical trials

View clinical trials related to Metabolic Syndrome X.

Filter by:

NCT ID: NCT01417871 Completed - Clinical trials for Weight Reduction in Patients With Metabolic Syndrome

ABC Program in Patients With Metabolic Syndrome

Start date: February 2010
Phase: N/A
Study type: Observational

Aims: We evaluate the efficacy of the "Active Body Control (ABC) Program" for weight reduction in patients with metabolic syndrome. Methods: The ABC program combines telemonitoring of the physical activity with a low-calorie diet also preferring carbohydrates with low glycemic indexes. In this 12-month, randomized, clinical trial 60 patients will be treated according to the ABC program and 60 control patients will receive standard therapy.

NCT ID: NCT01414647 Completed - Metabolic Syndrome Clinical Trials

The Health Effect of Diet Rich in Nordic Berries

Berry
Start date: January 2006
Phase: N/A
Study type: Interventional

Dietary polyphenols might have beneficial effects on glucose and lipid metabolism based on the studies made in animals or cell cultures. The findings regarding the possible decrease of low-grade inflammation are existing also in humans. Low-grade inflammation has been suggested to be a mechanistic link between obesity and its consequences on cardiometabolic health. The aim of the present study is to examine the effect of diet rich in berries on glucose and lipid metabolism and inflammatory markers.

NCT ID: NCT01412476 Completed - Metabolic Syndrome Clinical Trials

Coenzyme Q10 and Vitamin A, C, E in Relation to the Oxidative Stress, Antioxidant Enzyme Activity and Inflammation in Subjects With Metabolic Syndrome

Start date: August 2010
Phase: N/A
Study type: Observational

Metabolic syndrome (MS) is a significant risk factor of cardiovascular disease. However, the relationships between coenzyme Q10, antioxidant vitamins (Vitamin A, C, E) and the prevention of the risk of MS are still inconsistent. The purposes of this study are going to investigate the relation of coenzyme Q10, antioxidant vitamins concentration with the blood lipid levels, the markers of lipid peroxidation (TBARS), antioxidant enzymes activities (catalase, glutathione peroxidase and superoxide dismutase), and the inflammatory markers (hs-CRP,IL-6 and adiponectin). The investigators will recruit MS patients (case group, n = 100) and age-gender matched healthy subjects from previous study(n = 105) as a control group . The inclusion criteria of MS are according to the Bureau of Health Promotion, Department of Health in Taiwan (2007).Hopefully, the results of this study could provide the information to what has been know in MS subjects. The investigators expect coenzyme Q10 or antioxidant vitamins could be a preventive supplement to reduce the risk of MS.

NCT ID: NCT01411293 Completed - Obesity Clinical Trials

Vasoprotective Activities of Low-Fat Milk in Individuals With Metabolic Syndrome

Start date: August 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to define whether the acute consumption of low-fat milk protects against postprandial vascular endothelial dysfunction by reducing oxidative stress responses that limit nitric oxide bioavailability to the vascular endothelium. The investigators hypothesis is that the consumption of low-fat milk will improve postprandial vascular endothelial function in an oxidative stress-dependent manner that allows greater nitric oxide (NO) bioavailability. The objectives of this study are to 1) examine improvements in postprandial vascular endothelial function in response to low-fat milk ingestion, 2) define low-fat milk-mediated improvements in circulating biomarkers of redox status, and 3) define the mechanism by which low-fat milk improves NO bioavailability. Collectively, the successful completion of these studies is expected to define NO mediated activities of low-fat milk that protect against vascular endothelial dysfunction in individuals at high risk for developing CVD.

NCT ID: NCT01410851 Completed - Metabolic Syndrome Clinical Trials

Pulses, Satiation, Food Intake and Blood Glucose

Start date: September 2009
Phase: N/A
Study type: Interventional

Pulses have the potential to be positioned as a food for body weight and metabolic control based on their composition, effects on rate of digestion and absorption of fat and carbohydrates, and effects on satiety. However, the role of individual pulses incorporated into a mixed meal on regulation of food intake, satiety and glycaemic control remains unclear. Therefore, the objective of our study was to determine the effects of ad libitum consumption of pulse meals (treatments) on food intake at an ad libitum pulse meal, food intake at an ad libitum pizza meal at four hours, subjective appetite and blood glucose.

NCT ID: NCT01408667 Completed - Clinical trials for Metabolic Cardiovascular Syndrome

Hyperinsulinemic Euglycemic Clamp Protocol

Start date: November 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to determine the safety and efficacy of TRC150094 in male patients with cardiometabolic risk. Cardiometabolic risk which is the overall risk of cardiovascular disease (CVD) and diabetes resulting from the presence of hypertension, HDL cholesterol, insulin resistance, dysglycemia and visceral obesity.

NCT ID: NCT01400724 Completed - Metabolic Syndrome Clinical Trials

Inofolic NRT and the Metabolic Syndrome

Start date: June 2011
Phase: N/A
Study type: Interventional

A prospective, randomized, controlled, open-label study will be carried out on 80 post-menopausal women affected by the metabolic syndrome (criteria are described in NIH ATP III). After a written informed consent, women will be randomly treated for 6 months with hypocaloric diet (control group) or with diet and a supplementation of myo-inositol 2000 mg plus cocoa polyphenols 30 mg and plus isoflavones 80 mg. will be given randomly Eighty post-menopausal women, affected by metabolic syndrome will be randomized into two groups: 40 treated with myo-inositol 2 g twice per day and forty treated with placebo for six months. The investigators hypothesize that the administration of myo-inositol would improve the insulin-receptor activity in these women, reducing insulin resistance.

NCT ID: NCT01394380 Completed - Obesity Clinical Trials

Reduction of Sweetened Beverages and Intrahepatic Fat

REDUCS
Start date: October 2011
Phase: N/A
Study type: Interventional

The study will enroll 68 overweight male and female subjects with a high (> 2 3dl-can soda/day) consumption of sweetened beverage per day. After a run-in period of 4 weeks, subjects will be randomized to either a 12-week intervention arm in which sweetened beverages will be replaced by artificially sweetened, calorie-free beverages, or to a control arm. The following measurements will be performed at the end of the run-in period and at the end of the intervention period - intrahepatic fat concentration - visceral fat volume - changes in day-long metabolic profile from baseline(plasma glucose, insulin, and triglyceride concentrations) - changes in food intake and daily energy, carbohydrate and sugars intake from baseline

NCT ID: NCT01371396 Completed - Obesity Clinical Trials

Effect of Dietary Macronutrient Composition

Start date: September 1, 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to understand why Hispanics who are overweight have a higher incidence of fatty liver disease.

NCT ID: NCT01367431 Completed - Metabolic Syndrome Clinical Trials

Xanthohumol and Metabolic Syndrome

Start date: August 2011
Phase: N/A
Study type: Observational

The purpose of this study is to determine the pharmacokinetics (PK) of xanthohumol (XN). Small amounts of xanthohumol occur naturally in hops, used to make beer, and XN is also found in beer itself. Studies in animals have shown that XN can lower blood sugar and blood lipids such as triglycerides, which can contribute to heart disease. The purpose of this study is to see how much of the XN is absorbed into the blood and how fast it leaves the body when taken by mouth. Once the PK study has been done, the investigators' long-term goal is to learn if xanthohumol can lower risk factors for heart disease and type-2 diabetes in humans.